194 related articles for article (PubMed ID: 38597154)
1. De-escalation of axillary treatment in the event of a positive sentinel lymph node biopsy in cT1-2 N0 breast cancer treated with mastectomy: nationwide registry study (BOOG 2013-07).
de Wild SR; van Roozendaal LM; de Wilt JHW; van Dalen T; van der Hage JA; van Duijnhoven FH; Simons JM; Schipper RJ; de Munck L; van Kuijk SMJ; Boersma LJ; Linn SC; Lobbes MBI; Poortmans PMP; Tjan-Heijnen VCG; van de Vijver KKBT; de Vries J; Westenberg AH; Strobbe LJA; Smidt ML
Br J Surg; 2024 Apr; 111(4):. PubMed ID: 38597154
[TBL] [Abstract][Full Text] [Related]
2. The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07).
van Roozendaal LM; de Wilt JH; van Dalen T; van der Hage JA; Strobbe LJ; Boersma LJ; Linn SC; Lobbes MB; Poortmans PM; Tjan-Heijnen VC; Van de Vijver KK; de Vries J; Westenberg AH; Kessels AG; Smidt ML
BMC Cancer; 2015 Sep; 15():610. PubMed ID: 26335105
[TBL] [Abstract][Full Text] [Related]
3. Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment.
Tinterri C; Canavese G; Gatzemeier W; Barbieri E; Bottini A; Sagona A; Caraceni G; Testori A; Di Maria Grimaldi S; Dani C; Boni L; Bruzzi P; Fernandes B; Scorsetti M; Zambelli A; Gentile D;
Br J Surg; 2023 Aug; 110(9):1143-1152. PubMed ID: 37471574
[TBL] [Abstract][Full Text] [Related]
4. Omitting completion axillary lymph node dissection after detection of sentinel node micrometastases in breast cancer: first results from the prospective SENOMIC trial.
Andersson Y; Bergkvist L; Frisell J; de Boniface J
Br J Surg; 2021 Sep; 108(9):1105-1111. PubMed ID: 34010418
[TBL] [Abstract][Full Text] [Related]
5. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
[TBL] [Abstract][Full Text] [Related]
6. Contemporary Axillary Management in cT1-2N0 Breast Cancer with One or Two Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database.
Stafford AP; Hoskin TL; Day CN; Sanders SB; Boughey JC
Ann Surg Oncol; 2022 Aug; 29(8):4740-4749. PubMed ID: 35451727
[TBL] [Abstract][Full Text] [Related]
7. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
[TBL] [Abstract][Full Text] [Related]
8. Trends on Axillary Surgery in Nondistant Metastatic Breast Cancer Patients Treated Between 2011 and 2015: A Dutch Population-based Study in the ACOSOG-Z0011 and AMAROS Era.
Poodt IGM; Spronk PER; Vugts G; van Dalen T; Peeters MTFDV; Rots ML; Kuijer A; Nieuwenhuijzen GAP; Schipper RJ
Ann Surg; 2018 Dec; 268(6):1084-1090. PubMed ID: 28742702
[TBL] [Abstract][Full Text] [Related]
9. Patterns of completion axillary dissection for patients with cT1-2N0 breast cancer undergoing total mastectomy with positive sentinel lymph nodes.
Schwieger L; Postlewait LM; Subhedar PD; Geng F; Liu Y; Gillespie T; Arciero CA
J Surg Oncol; 2024 Mar; 129(3):468-480. PubMed ID: 37955191
[TBL] [Abstract][Full Text] [Related]
10. De-escalation of axillary surgery in patients outside Z0011 criteria.
Giannakou A; Gooch J; Gergelis KR; Weiss A
Surgery; 2023 Aug; 174(2):416-418. PubMed ID: 37156648
[TBL] [Abstract][Full Text] [Related]
11. Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.
de Boniface J; Filtenborg Tvedskov T; Rydén L; Szulkin R; Reimer T; Kühn T; Kontos M; Gentilini OD; Olofsson Bagge R; Sund M; Lundstedt D; Appelgren M; Ahlgren J; Norenstedt S; Celebioglu F; Sackey H; Scheel Andersen I; Hoyer U; Nyman PF; Vikhe Patil E; Wieslander E; Dahl Nissen H; Alkner S; Andersson Y; Offersen BV; Bergkvist L; Frisell J; Christiansen P; ;
N Engl J Med; 2024 Apr; 390(13):1163-1175. PubMed ID: 38598571
[TBL] [Abstract][Full Text] [Related]
12. Axillary management for young women with breast cancer varies between patients electing breast-conservation therapy or mastectomy.
Tadros AB; Moo TA; Stempel M; Zabor EC; Khan AJ; Morrow M
Breast Cancer Res Treat; 2020 Feb; 180(1):197-205. PubMed ID: 31938938
[TBL] [Abstract][Full Text] [Related]
13. Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohort.
Costaz H; Boulle D; Bertaut A; Rouffiac M; Beltjens F; Desmoulins I; Peignaux K; Ladoire S; Causeret S; Loustalot C; Padeano MM; Vincent L; Jankowski C; Arnould L; Coutant C
Bull Cancer; 2022 Mar; 109(3):268-279. PubMed ID: 34838310
[TBL] [Abstract][Full Text] [Related]
14. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
Hennigs A; Köpke M; Feißt M; Riedel F; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Schneeweiss A; Heil J
Breast Cancer Res Treat; 2019 Jan; 173(2):429-438. PubMed ID: 30315437
[TBL] [Abstract][Full Text] [Related]
15. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
[TBL] [Abstract][Full Text] [Related]
16. Oncological Safety of Skipping Axillary Lymph Node Dissection in Patients with Clinical N0, Sentinel Node-Positive Breast Cancer Undergoing Total Mastectomy.
Chun JW; Kang E; Kim HK; Lee HB; Moon HG; Lee JW; Han W
Ann Surg Oncol; 2024 May; 31(5):3168-3176. PubMed ID: 38368292
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic accuracy of sentinel lymph node biopsy in determining the axillary lymph node metastasis.
Okur O; Sagiroglu J; Kir G; Bulut N; Alimoglu O
J Cancer Res Ther; 2020; 16(6):1265-1268. PubMed ID: 33342782
[TBL] [Abstract][Full Text] [Related]
18. Risk factors of non-sentinel lymph node metastasis in breast cancer with 1-2 sentinel lymph node macrometastases underwent total mastectomy: a case-control study.
Huang Z; Wu Z; Zou QQ; Xie YJ; Li LH; Huang YP; Wu FM; Huang D; Pan YH; Yang JR
World J Surg Oncol; 2023 Apr; 21(1):125. PubMed ID: 37024930
[TBL] [Abstract][Full Text] [Related]
19. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
[TBL] [Abstract][Full Text] [Related]
20. Extracapsular extension in the positive sentinel lymph node: a marker of poor prognosis in cT1-2N0 breast cancer patients?
Vane MLG; Willemsen MA; van Roozendaal LM; van Kuijk SMJ; Kooreman LFS; Siesling S; de Wilt HHW; Smidt ML
Breast Cancer Res Treat; 2019 Apr; 174(3):711-718. PubMed ID: 30610488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
